Molecular diagnosis and treatment of meningiomas: an expert consensus (2022).

Authors :: Deng J
Hua L
Bian L
Chen H
Chen L
Cheng H
Dou C
Geng D
Hong T
Ji H
Jiang Y
Lan Q
Li G
Liu Z
Qi S
Qu Y
Shi S
Sun X
Wang H
You Y
Yu H
Yue S
Zhang J
Zhang X
Wang S
Mao Y
Zhong P
Gong Y
Source :: Chinese medical journal [Chin Med J (Engl)] 2022 Aug 20; Vol. 135 (16), pp. 1894-1912. Date of Electronic Publication: 2022 Aug 20.
Publication Year :: 2022
Abstract: Abstract: Meningiomas are the most common primary intracranial neoplasm with diverse pathological types and complicated clinical manifestations. The fifth edition of the WHO Classification of Tumors of the Central Nervous System (WHO CNS5), published in 2021, introduces major changes that advance the role of molecular diagnostics in meningiomas. To follow the revision of WHO CNS5, this expert consensus statement was formed jointly by the Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Association together with neuropathologists and evidence-based experts. The consensus provides reference points to integrate key biomarkers into stratification and clinical decision making for meningioma patients.<br />Registration: Practice guideline REgistration for transPAREncy (PREPARE), IPGRP-2022CN234.<br /> (Copyright © 2022 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.)